Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway.

Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM.

J Am Coll Surg. 2007 May;204(5):764-73; discussion 773-5. Epub 2007 Feb 23.

2.

Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.

Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, Patsouris E, Tseleni-Balafouta S.

Endocr Pathol. 2010 Jun;21(2):90-100. doi: 10.1007/s12022-010-9112-0.

PMID:
20186503
3.

The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.

Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT.

J Transl Med. 2011 Nov 22;9:200. doi: 10.1186/1479-5876-9-200.

4.

Coexistence of papillary thyroid cancer with Hashimoto thyroiditis.

Konturek A, BarczyƄski M, Wierzchowski W, Stopa M, Nowak W.

Langenbecks Arch Surg. 2013 Mar;398(3):389-94. doi: 10.1007/s00423-012-1021-x. Epub 2012 Oct 26.

5.

Osteopontin levels in patients with papillary thyroid cancer according to the presence of Hashimoto's thyroiditis.

Park SH, Park CS, Kim YI, Nam-Goong IS, Kim YS, Lee JC, Choi JI, Park JW, Kim ES.

Asian Pac J Cancer Prev. 2015;16(6):2447-51.

6.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

7.

Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.

Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.

Asian Pac J Cancer Prev. 2015;16(7):2645-51.

8.

Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Xing M.

Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646. Review.

9.

Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.

Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.

PLoS One. 2012;7(2):e30427. doi: 10.1371/journal.pone.0030427. Epub 2012 Feb 17.

10.

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.

Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.

Oncol Rep. 2013 Aug;30(2):623-36. doi: 10.3892/or.2013.2512. Epub 2013 May 31.

PMID:
23728071
11.

Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization.

Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, Palmieri E, Pezzullo L, Palombini L, Fusco A, Viglietto G.

Am J Pathol. 2005 Mar;166(3):737-49.

12.

High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.

Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B, Zhu G, Condouris S, Xing M.

J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90. Epub 2007 Apr 10.

PMID:
17426084
13.

Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer.

Ahn D, Heo SJ, Park JH, Kim JH, Sohn JH, Park JY, Park SK, Park J.

Acta Oncol. 2011 Nov;50(8):1228-34. doi: 10.3109/0284186X.2011.602109. Epub 2011 Aug 28.

PMID:
21871002
14.

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.

Milosevic Z, Pesic M, Stankovic T, Dinic J, Milovanovic Z, Stojsic J, Dzodic R, Tanic N, Bankovic J.

Transl Res. 2014 Nov;164(5):411-23. doi: 10.1016/j.trsl.2014.06.005. Epub 2014 Jun 23.

PMID:
25016932
15.

PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.

Guigon CJ, Zhao L, Willingham MC, Cheng SY.

Oncogene. 2009 Jan 29;28(4):509-17. doi: 10.1038/onc.2008.407. Epub 2008 Nov 10.

16.

PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.

Huang FF, Zhang L, Wu DS, Yuan XY, Yu YH, Zhao XL, Chen FP, Zeng H.

PLoS One. 2014 Mar 6;9(3):e88298. doi: 10.1371/journal.pone.0088298. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99917.

17.

Coexistence of papillary thyroid cancer and Hashimoto thyroiditis in children: report of 3 cases.

Koibuchi H, Omoto K, Fukushima N, Toyotsuji T, Taniguchi N, Kawano M.

J Ultrasound Med. 2014 Jul;33(7):1299-303. doi: 10.7863/ultra.33.7.1299.

18.

TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.

Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, Lai JM.

Oncogene. 2012 May 10;31(19):2389-400. doi: 10.1038/onc.2011.419. Epub 2011 Sep 26.

PMID:
21996732
19.

INPP4B Is a Tumor Suppressor in the Context of PTEN Deficiency.

Vo TT, Fruman DA.

Cancer Discov. 2015 Jul;5(7):697-700. doi: 10.1158/2159-8290.CD-15-0609.

Items per page

Supplemental Content

Write to the Help Desk